The reduction in price target by Baird, as indicated by analyst Joel Beatty, could lead to a negative short-term impact on Amylyx Pharma's stock price. This adjustment reflects a less optimistic outlook on the company's valuation, potentially influencing investor sentiment and stock performance negatively in the short term.